Athersys Announces Positive Results From Its Exploratory Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress Syndrome (ARDS)

Stock Information for Athersys Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athersys Inc.

Athersys to Host Investor Day in New York City
Athersys to Host First Quarter Financial Results Call
Athersys to Participate in Two Upcoming Healthcare Conferences
Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Athersys to Host Year-End 2018 Financial Results Call
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
Athersys Reports Third Quarter 2018 Results
Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC Investment - Emerging Consolidated Expectations, Analyst Ratings

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.